“`html
Nyxoah expands Manufacturing to Liège, Belgium to Address Sleep Apnea
Published: 2026/01/22 12:46:04
Addressing a Global health Crisis
Nyxoah, a Belgian medical technology company, is bolstering its industrial operations with a new facility in Liège, Belgium. This expansion is centered around the production of its innovative Genio system, a device designed to treat obstructive sleep apnea (OSA), a condition affecting an estimated one billion people worldwide [[3]]. OSA is characterized by repeated interruptions in breathing during sleep, leading to significant health risks including cardiovascular disease and increased mortality.
The Genio System: A Novel Approach to Sleep Apnea Treatment
The Genio system represents a unique approach to treating OSA. Unlike conventional Continuous Positive Airway Pressure (CPAP) therapy, which requires a mask and constant airflow, Genio is a battery-free, leadless neurostimulator implanted during a minimally invasive procedure. [[3]] It works by gently stimulating the hypoglossal nerve, which controls the tongue, keeping the airway open during sleep. According to Olivier Taelman, CEO of Nyxoah, “Our system, named Genio, stimulates the nerve that controls the tongue to keep the airways open during sleep.”
Strategic Location and Manufacturing plans
The decision to establish a manufacturing presence in Liège was driven by the city’s supportive ecosystem for life sciences and its modern infrastructure. Nyxoah plans to develop and produce key components of the Genio system at the LégiaPark facility. This will complement the company’s